- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03976271
Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses (HCIR)
Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses in Patients With Diabetes Mellitus Type 1, Type 2 and Healthy Volunteers
Study Overview
Status
Intervention / Treatment
Detailed Description
Objectives: The overall aim of the present study is to investigate the effect of hypoglycaemia on cardiovascular and inflammatory responses, molecular mechanisms and epigenetic profiles in various groups of people with diabetes type 1, type 2 and healthy volunteers.
Study design: Intervention study
Intervention: All subjects will undergo a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp (nadir 2.8 mmol/L), during and after which blood and urine will be sampled for further examination for up to one week.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nordsjaelland
-
Hillerød, Nordsjaelland, Denmark, 3400
- Nordsjællands University Hospital
-
-
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6525 GA
- Radboudumc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Overall inclusion criteria
- Ability to provide written informed consent
- Must be able to speak and read Danish (for Hillerød-site) and Dutch (for Nijmegen-site)
- Insulin treatment according to basal-bolus insulin regimen (injections or insulin pump) (except for group 5)
- Body-Mass Index: 19-40 kg/m2
- Age ≥18 years, ≤ 80 years
- Blood pressure: <140/90 mmHg
- Duration of diabetes > 1 year (except for group 5)
- HbA1c < 100 mmol/mol
Group specific
- Group 1: HbA1c >64 mmol/mol
- Group 2: impaired awareness of hypoglycaemia (IAH) as assessed by a score of ≥3 on the modified Clarke questionnaire, ≥4 on the Gold questionnaire and a positive score on the Pedersen-Bjergaard questionnaire.
- Group 3: normal awareness of hypoglycaemia (NAH) as assessed by a score of <3 on the modified Clarke questionnaire, <4 on the Gold questionnaire and a negative score on the Pedersen-Bjergaard.
- Group 4: Insulin treatment for at least 1 year
- Group 5/6: HbA1c <42 mmol/mol
Exclusion Criteria:
- - Severe medical or psychological conditions interfering with the perception of hypoglycaemia other than IAH such as brain injuries, epilepsy, a major cardiovascular disease event or anxiety disorders
- Use of immune-modifying drugs or antibiotics
- Treatment with glucose-modifying (other than insulin, SGLT-2 inhibitors and metformin) agents (e.g. prednisolon)
- Use of anti-depressive drugs
- Pregnancy or breastfeeding or unwillingness to undertake measures for birth control
- Use of statins (e.g. stop statins >2 weeks before performing blood sampling. This can be safely done in the context of primary prevention)
- Any event of cardiovascular disease in the past 5 years (e.g. myocardial infarction, stroke, heart failure, symptomatic peripheral arterial disease)
- Auto-inflammatory or auto-immune diseases
- Any infection in past three months
- Previous vaccination in the past three months
- Laser coagulation for proliferative retinopathy in the past six months
- Proliferative retinopathy
- Diabetic nephropathy as reflected by an albumin-creatinine ratio ˃ 30 mg/gor an estimated glomerular filtration rate (by MDRD) ˂60ml/min/1.73m2
- History of pancreatitis (acute or chronic) or pancreatic cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: T1DM poor glycaemic control
patients with type 1 diabetes and poor glycaemic control (HbA1c >8% / >64 mmol/mol will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
|
For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia.
This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
Other Names:
|
Active Comparator: T1DM impaired awareness
patients with type 1 diabetes and impaired awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
|
For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia.
This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
Other Names:
|
Active Comparator: T1DM Normal awareness
patients with type 1 diabetes and normal awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
|
For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia.
This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
Other Names:
|
Active Comparator: T2DM + Insulin
patients with type 2 diabetes with insulin treatment for at least 1 year will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
|
For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia.
This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
Other Names:
|
Active Comparator: Healthy control T2DM
healthy controls without diabetes and age, gender and BMI matched with diabetes type 2 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
|
For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia.
This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
Other Names:
|
Active Comparator: Healthy control T1DM
Healthy controls without diabetes and age, gender and BMI matched with diabetes type 1 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
|
For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia.
This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA
Time Frame: 1.5 year
|
Cytokine production (TNF-alfa, IL-6, IL-10 and IL-1β) of isolated and stimulated monocytes
|
1.5 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Atherogenic responses of (recurrent) hypoglycaemia using foam cell formation.
Time Frame: 1.5 year
|
Measurement of Ox-LDL uptake by measuring intracellular apolipoproteine B
|
1.5 year
|
Metabolomics profile of each group
Time Frame: 1.5 year
|
Un-targeted metabolomics and identification of metabolites based on exact mass using metabolomics library
|
1.5 year
|
Epigenetic modifications
Time Frame: 1.5 year
|
Epigenetic modifications due to hypoglycaemia in the promoter regions of the pro-inflammatory cytokines in monocytes
|
1.5 year
|
Cardiac function responses to hypoglycaemia using echocardiography
Time Frame: 1.5 year
|
Cardiac function responses to hypoglycaemia using echocardiography
|
1.5 year
|
Cognitive function responses to hypoglycaemia using cognitive function tests (TAP, PASAT)
Time Frame: 1.5 year
|
Amount of correct answers
|
1.5 year
|
Oxidative stress responses using oxidative stress marker
Time Frame: 1.5 year
|
Excretion of guanine nucleosides in urine (ng/mL)
|
1.5 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Bastiaan E de Galan, MD, PhD, Radboud University Medical Center
- Principal Investigator: Ulrik Pedersen-Bjergaard, MD, PhD, Nordsjællands University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCIR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
DiabeloopUniversity Hospital, Grenoble; AGIR à Dom; Icadom; Centre Hospitalier Annecy Genevois and other collaboratorsCompletedDiabetes Mellitus Type 2 - Insulin-TreatedFrance
Clinical Trials on hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
-
University of MinnesotaCompleted
-
University of Maryland, BaltimoreNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of AarhusThe Novo Nordic Foundation; The Danish Medical Research Council; The Danish Diabetes...Completed
-
Brigham and Women's HospitalBeth Israel Deaconess Medical Center; Boston Children's Hospital; Mclean HospitalRecruitingHypoglycemia | Physiological StressUnited States
-
Yale UniversityWithdrawnDiabetes Mellitus | Fibrous Dysplasia | McCune-Albright Syndrome | Intraductal Papillary Mucinous NeoplasmUnited States
-
Vanderbilt UniversityCompleted
-
Vanderbilt UniversityCompletedInsulin Resistance | Type 1 Diabetes Mellitus | Maturity-Onset Diabetes of the Young, Type 2 | MODY2United States
-
German Diabetes CenterCompletedNewly Diagnosed Type 2 Diabetes (During the Last 12 Months)Germany
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedT2D | IGT - Impaired Glucose ToleranceUnited States
-
Medical University of GrazMerck Sharp & Dohme LLCCompletedDiabetes Mellitus, Type 2 | Hypoglycemia | Diabetes Mellitus With Hypoglycemia | Hypoglycemic EpisodeAustria